BioVie Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BIVIW | BIIB | ABVC | BHVN | ABBV | B9A.F | |
|---|---|---|---|---|---|---|
| Market cap | — | 36.63B | 26.69M | 2.11B | 518.11B | 2.45B |
| P/E (TTM) | — | 107.3 | — | — | 50.4 | 251.5 |
| Forward P/E | — | 15.2 | -2.3 | -7.5 | 18.1 | — |
| Price/book | — | 1.9 | 2.5 | -21.4 | -113.0 | 1.2 |
| Dividend yield | — | — | — | — | 2.35% | 0.68% |
| 1-year change | — | +62.35% | −64.79% | +78.66% | +34.60% | +13.08% |
| Today | +12.12% | −2.61% | 0.00% | −8.53% | −0.58% | 0.00% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All BIVIW news ›BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
Dr. Penelope Markham, BioVie’s Senior Vice President and Program Lead for Long COVID, will share results from the Company’s Phase 2 ADDRESS-LC trial evaluating bezisterim for the treatment of the ... BioVie Invited to Present Data on…
BioVie presents Phase 2 data on bezisterim in Long COVID
BioVie (BIVI) announced the presentation of results from the Phase 2 ADDRESS-LC study evaluating bezisterim in patients with Long COVID at the 1... BioVie presents Phase 2 data on bezisterim in Long COVID BioVie (BIVI) announced the…
BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
Bezisterim was well tolerated, with a favorable safety profile compared with placebo. Treatment-emergent adverse events (TEAEs) occurred in 39.3% of bezisterim-treated participants and 51.7% of placebo-treated participants. No severe or…
BioVie showcases Long COVID and Parkinson’s data at ANA2026, with findings in Annals of Neurology
Proactive has a commercial relationship with BioVie Inc. This article was produced independently under Proactive's Editorial Standards Policy. BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do joined Proactive's Stephen Gunnion after the…
BioVie reports positive Phase 2 Parkinson’s data for bezisterim
Proactive has a commercial relationship with BioVie Inc. This article was produced independently under Proactive's Editorial Standards Policy. BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson’s drug bezisterim…
BioVie (NASDAQ:BIVI) Stock Rating Cut to “Sell” at Wall Street Zen
BioVie (NASDAQ:BIVI – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Monday, Wall Street Zen reports. Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of…
Small cap wrap: Great Plains Metals, Thor Explorations, Uranium American Resources, BioVie...
The transaction closed under a share exchange agreement that made TEG the principal operating business of the combined public company. It will operate as TEG Overseas, Inc., with its common stock trading on the OTC Markets. Greenland…
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVI
BioVie completes treatment phase of ADDRESS-LC trial
BioVie (BIVI) announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological... BioVie completes treatment phase of ADDRESS-LC trial BioVie (BIVI) announced that the last…
BioVie announces topline results from ADDRESS-LC trial
BioVie (BIVI) announced topline results from the company’s Phase 2 ADDRESS-LC trial evaluating its investigational drug candidate bezisterim, an... BioVie announces topline results from ADDRESS-LC trial BioVie (BIVI) announced topline…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com7
- proactiveinvestors.com4
- defenseworld.net1
- nasdaq.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.